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Abstract: The gene EHMT1 that encodes the Euchromatic Histone Methyltransferase-1, also
known as GLP (G9a-like protein), has been associated with a number of neurodevelopmental and
neurodegenerative disorders. GLP is a member of the euchromatic lysine histone methyltransferase
family, along with EHMT2 or G9A. As its name implies, Ehmt1/GLP is involved in the addition
of methyl groups to histone H3 lysine 9, a generally repressive mark linked to classical epigenetic
process such as genomic imprinting, X-inactivation, and heterochromatin formation. However, GLP
also plays both a direct and indirect role in regulating DNA-methylation. Here, we discuss what
is currently known about the biochemical function of Ehmt1/GLP and its association, via various
genetic studies, with brain disorders.
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1. Introduction
Euchromatic Histone Methyltransferase-1 (EHMT1), also known as GLP (G9a-like protein), is a
member of the euchromatic lysine histone methyltransferase family, along with EHMT2 or G9A [1–3].
These two proteins are part of a superfamily of lysine methyltransferases that are characterised by the
presence of a SET domain. Within this superfamily GLP and G9A are a part of the Suv39h1 family
of lysine methyltransferases responsible for the mono-, di-, and tri-methylation at lysine residues [4].
The SET/pre-SET domains have been identified as key formethyltransferase activity [5]. These proteins,
and their methyltransferase activity, are highly conserved through evolution with a large number of
orthologues having been characterised in other species, including EHMT in Drosophila melanogaster,
encoded by a single gene that appears to share functional similarities with both GLP and G9a [6].
Both GLP and G9A also uniquely contain ankyrin repeats in their protein structure. These ankyrin
repeats, although unique within the methyltransferase family of proteins, are also found in a wide
range of proteins with differing functions including cell adhesion and synaptic functioning [7,8].
Ankyrin repeats are believed to be important for protein-protein interactions, suggesting a similar
role GLP and G9a [9]. The Ank domains in GLP and G9a have been shown to preferentially bind to
Histone 3 (H3) tails at mono- and di-methylated K9 [10], providing evidence of the proteins being able
to recognise the marks.
Although widely recognised as histone methyltransferases, there is growing evidence of the
SET domain superfamily of enzymes interacting with other proteins. GLP and G9a have both
been identified to methylate non-histone target proteins such as WIZ, a zinc finger protein with
which GLP/G9a form a stable repressive complex [11]; p53, a tumour suppressor [12]; and CDYL,
a RE1-Silencing Transcription factor (REST) co-repressor [11]. GLP has also been found to target
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DNA methyltransferases, DNMT1 and DNMT3/3a [13]. For the most part, the greater roles of these
interactions are not understood.
2. Methyltransferase Activity
GLPmediates the addition of mono- and di- methyl groups to the lysine 9 (K9) position on histone
H3 within euchromatic regions of the genome, doing so via its catalytic SET/pre-SET domains [1,2].
This is generally associated with repression of transcription, and is associated with classical epigenetic
mechanisms of transcriptional silence such as X-inactivation [14], genomic imprinting [15,16], and
globally within regions of heterochromatin [17]. GLP is often found within repressive complexes, and
notably forms a stoichiometric complex with G9a that appears to be vital for in vivo dimethylation
at H3K9 [2]. GLP is also a member of a large complex that includes the Neuron-Restrictive Silencer
Factor (NRSF/REST) repressive unit important for repressing neuronal genes in progenitors [18,19].
Finally, GLP has been shown to also form a mega complex with G9a, SETDB1, and Suv39h1 that, in
turn, appears to regulate G9a target genes [20].
Despite apparent redundancy in the overlapping function of GLP and G9a, Tachibana et al.
(2005) [2] showed that knocking out either protein leads to significantly reduced H3K9 dimethylation,
with no further reduction being seen in a double knockout, suggesting a lack of compensation of
function by either GLP or G9A. Furthermore, homozygous deletion of GLP leads to embryonic lethality
in mice, suggesting a critical role during development that cannot be compensated for by the G9a alone.
This central importance for a role in development is complimented with evidence of GLP repressing
E2F/MYC-responsive genes important for cell cycle regulation [21] and its aforementioned role in
REST complex [19].
3. DNAMethylation
There is growing evidence for the involvement of GLP and the repressive chromatin mark
H3K9me2 in the re-establishment and maintenance of DNA methylation. DNA methylation needs to
be re-established upon the formation of the hemi-methylated daughter strands after DNA replication.
A reduction of either GLP or G9A leads to a decrease in DNA methylation [22], and H3K9me2 marks
appear necessary for the maintenance process [23,24]. There is some evidence of DNMT1 interacting
with G9a, regulating H3K9 methylation in the HCT116 cancerous colon immortalised cells, where
knocking out DNMT1 lead to a reduction in H3K9me2 [25]. Low DNA methylation in embryonic stem
cells (ESCs) cultured in 2i serum was associated with decreased DNA methylation maintenance and
associated protein E3 ubiquitin-protein ligase (UHRF1) and decreased GLP/G9a expression, coupled
with an upregulation of several H3K9 demethylases [26]. However, the exact mechanism by which GLP
mediates the maintenance of DNAmethylation is not fully understood. UHRF1 is known to co-localise
and directly interact with DNMT1 and aids in the maintenance of the methylation. Through its
SET/RING domain it binds preferentially to hemi-methylated DNA, recruiting DNMT1 to re-establish
methylation [27,28]. UHRF1 was also shown to bind to H3K9me2/3 through its tandem Tudor
domain and appears to bind DNMT1 to mediate DNA methylation maintenance in an H3K9me2/3
dependent manner [27]. A recent paper however has increased the current understanding of this
process; DNA ligase 1 (LIG1), a novel target of GLP is methylated on its H3K9 mimic, UHRF1 then
binds to the mimic, and in turn this binding leads to the recruitment of UHRF1 to hemi-methylated
sites, mediating its activity [29] (Figure 1). UHRF1 was also found to more readily bind to the LIG1
mimic compared to H3K9me2/3. Current evidence is suggestive of complimentary role of GLP in
histone and DNA methylation.
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Figure 1. Maintenance of DNA methylation: Glp and G9a are known to target H3K9 for mono and
di-methylation, they have also recently been found to methylate the H3K9 mimic on DNA ligase 1
(LIG1). UHRF1 can recognise and bind both H3K9me2/3 marks as well as the methylated mimic
on LIG1. UHRF1 binds to methylated LIG1 with a high affinity, this in turn mediates its activity to
recognise and preferentially bind to hemi-methylated DNA strands, recruiting DNA methyltransferase
1 (DNMT1) to re-establish methylation and CpG islands.
4. GLP in Brain Disorder
In humans, the gene encoding GLP, EHMT1, is found on the long arm of chromosome 9,
specifically at q34.3. A range of genetic studies has linked loss (haploinsufficiency) or mutation
of one copy of this gene with a number of brain disorders, particularly neurodevelopmental
disorders. These data add to the growing image of neurodevelopmental disorders being, in part,
“epigeneopathies”, as GLP and various other important enzymes in histone modification have been
implicated in the pathogenesis of neurodevelopmental disorders (reviewed in [30]).
4.1. Intellectual Disability
Intellectual disability affects approximately 1–3% of the population and is characterised by
reduced cognitive ability and some adaptive behaviour problems [31]. Intellectual disability can be
sporadic and isolated, or as an identifying phenotype in a complex syndrome and is a key symptom in
various syndromes including Down syndrome and fragile X syndrome [30].
GLP is most notably associated with Kleefstra syndrome, an intellectual disability multi-system
syndrome associated with congenital heart defects, hypotonia, and dysmorphisms [32]. Kleefstra
syndrome is caused by the haploinsufficiency of GLP, either through single mutations or 9q34.3
microdeletions [32,33]. More recently, a sub-group of patients suffering from Kleefstra syndrome that
do not have the deletion or mutation of GLP have been identified. Interestingly however, whilst GLP
appears genetically intact in this sub-group, individuals do carry mutations in other genes known
to directly interact with GLP, such as MBD5, another epigenetic regulator [34]. This has helped the
development of the central role of GLP in the pathogenesis of Kleefstra syndrome, and its larger impact
in epigenetic regulation.
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Outside of Kleefstra syndrome, de novo deletions of GLP have been detected in severe intellectual
disability Copy Number Variant (CNV studies) [35–37], and GLP associated chromatin regulators
have also been linked to sporadic intellectual disability in chromosomal microarray [37]. Furthermore,
exome studies of patients with intellectual disability again link GLP to a wider epigenetic regulatory
network important to cognitive function [31,38]. Recently, exome sequencing of approximately
4300 families with members suffering from developmental disorders identified GLP as a genome-wide
significant candidate in the pathogenesis of developmental disorders generally [39]. Finally, GLP
has also been identified as a pathogenic CNV in patients with intellectual disability and early onset
epilepsy [40]. Epilepsy is often associated with ID and developmental delay [38,40], and some patients
with Kleefstra syndrome are also known to be comorbid with epilepsy [41].
4.2. Autistic Spectrum Disorders
GLP has also been associated with autism spectrum disorders (ASDs). ASDs share a common
base of phenotypes including dysfunctional social behaviour and restricted adaptive and repetitive
behaviours [42]. Interestingly, ASD is also highly co-diagnosed in Kleefstra syndrome patients [43] and
is known to be comorbid with a range of other developmental disorders and intellectual disability [44].
CNV analysis of ASD probands identified GLP as de novo mutation [45]. This evidence is strengthened
by a recent study where BCA (balanced chromosomal abnormalities) sequencing of 22 autism patients
identified GLP microdeletions as a risk in the development of ASD [46]. Finally, exon sequencing of
Japanese autism patients also identified two novel rare missense GLP and G9a variants. G9a has also
been shown to be elevated in the blood of these ASD patients, suggesting an increasingly restrictive
chromatin in the pathogenesis of ASD [47]. These studies link GLP to the overlapping phenotypes
seen in intellectual disability disorders and autism.
4.3. Schizophrenia and Psychosis
Schizophrenia affects approximately 1% of the population. This highly heterogeneous diagnosis
is regarded to share a genetic basis with various other developmental and psychiatric disorders,
particularly autism spectrum disorders [48,49]. A population based study showed an overlapping
co-diagnosis of schizophrenia and intellectual disability, with over 30% of patients diagnosed with
intellectual disability being co-diagnosed with a psychiatric illness, of which schizophrenia was
overrepresented [50]. Recently, a copy number variation analysis study [51] identified two de novo
GLP CNVs as pathogenic variants in schizophrenia, linking GLP to the pathogenesis of the adult onset
psychiatric disorder. Interestingly, diagnosis of schizophrenia was associated with increased GLP and
H3K9me2 in post-mortem brain samples, and increased GLP expression was also linked to worsening
symptoms [52]. Increased GLP and H3K9me2 marks, and thus a restrictive chromatin state, as seen
in ASD, could possibly therefore be considered a marker for schizophrenia, as well as a marker for
potential prognosis.
Interestingly, there is now growing evidence that Kleefstra syndrome patients have developed
regressive phenotype, and develop adult onset psychosis [53,54]. Therefore, either maintained
reduction of GLP’s function, or an early developmental trigger due to GLP haploinsufficiency leads
to psychosis in adulthood. Evidence presented here shows that both an increase and decrease in
GLP and H3K9me2 appears to lead to similar phenotypes in psychosis, pointing towards GLP’s
importance in maintaining the homeostasis of the epigenome, and changes in either direction would
lead to impairment.
4.4. Evidence of H3K9me2 in Neurodegeneration
H3K9me2, a marker of heterochromatin, initiated by G9A and GLP has been associated with
neurodegeneration in human and animal models. H3K9 methylation is found to increase with
age, and is linked to cognitive decline. Perhaps as a further link with pathological aging, H3K9
methylation was increased in the brains of 3xTg-AD mouse model of Alzheimer’s disease [55].
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Conversely however, in post-mortem brains of Alzheimer disease patients H3K9me2 was in fact
reduced, this was complimented by reduced H3K9me2 in Tau neurodegenerative Drosophila and
mouse models, where there is evidence of global loss of heterochromatin [56]. α-Synuclein, a protein
associated with Parkinson’s disease and other neurodegenerative disorders, was found to increase
the levels of H3K9me2, and overexpression of the protein would lead to an increasingly restrictive
chromatin in Parkinson’s disease [57]. H3K9me2 has also been associated with Huntington’s disease
(HD), where the marker is shown to be in the striatum of HD patients [58]. The growing evidence
of H3K9me2 in the pathogenesis of neurodegenerative disorders is of notable interest due to the
previously mentioned regressive phenotype in Kleefstra syndrome patients, with patients showing
increased severity in behavioural and motor deficiencies, developing apathy, and also showing signs of
subcortical abnormalities [53], suggesting a neurodegenerative course in Kleefstra syndrome prognosis.
5. Conclusions
EHMT1/GLP can be regarded as a key regulator in neurodevelopment, and thus has been
widely identified in neurodevelopmental and, to a lesser extent, neurodegenerative disorders.
Interestingly, the neurodevelopmental disorders in which EHMT1/GLP has been associated are
known to share a molecular pathogenesis, with many of them often being comorbid in their nature.
GLP, due to its dynamic function, has been identified in these studies as a cross diagnostic risk
factor. From microdeletions to missense variations and single mutations, it would appear GLP has a
pleiotropic effect on development and developmental disorders: from early autistic phenotypes to a
more regressive phenotype and development of psychosis in the adult, as seen in Kleefstra patients. It
may very likely continue on to lead to a more degenerative phenotype, with various neurodegenerative
disorders showing a pathogenesis linked to continued imbalance in H3K9me2 markers.
Examining the role epigenetics as a whole on the pathogenesis of neurodevelopmental disorders,
with GLP as an example, will lead to a better understanding of their pathogenesis that will likely help
inform the involvement of other non-epigenetic genes to lead away from narrow pathogenic tracks
such as ‘synaptopathies’ to a more elaborate framework of developmental genes and environment.
The understanding of this interplay is of high importance for novel and improved treatments of brain
disorders, either by the direct targeting of epigenetic regulators or through targeting upstream and
downstream mechanisms identified through basic studies of their modes of action.
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